Search Results - "Yong, W.P."

1255P da VINci: Safety and efficacy of the OTSGC-A24 vaccine and nivolumab in metastatic gastric cancer by Choo, J., Rha, S.Y., Jung, M., Tan, H.L., Chan, G., Ho, J.S., Walsh, R.J., Chee, C.E., Raghav, S., Yong, W.P.

Get full text

2282P Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma by Low, Q.J., Looi, W.D., Sukumar, S.J., Ang, Y., Wong, A.S., Soo, R.A., Sundar, R., Lum, J., Chee, C.E., Bonney, G. Kunnath, Tan, H.L., Yong, W.P.

Get full text

1600P Low dose pembrolizumab is effective in the treatment of advanced non-small cell lung cancer (NSCLC) with reduced cost by Low, J.L., Sooi, K.W.X., Huang, Y.Q., Chan, Z.Y., Soo, R., Raghav, S., Yong, W.P.

Get full text

82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies by Choo, J., Nathan Jeraj, S., Chan, G., Sundar, R., Yong, W.P., Lee, M., Ngoi, N.Y.L., Wong, A., Soo, R.A., Chee, C.E., Lim, J., Goh, B-C., Lee, S.C., Tan, D.S.

Get full text

146P Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study by Lee, K-W., Kang, Y-K., Chen, M-H., Hirano, H., Sunakawa, Y., Kim, S.T., Lin, C-C., Yong, W.P., Kawakami, T., Oshima, T., Li, Z., Hopkins, M., Levin, A., Wang, H., Goldstein, L., Zhou, D., Rha, S.Y.

Get full text

1550P Evaluating the novel combination of pressurized intraperitoneal aerosol chemotherapy-oxaliplatin (PIPAC-OX) as an immunomodulator in combination with systemic nivolumab for gastric cancer peritoneal metastases by Sundar, R., Chia, D., Ceelen, W., Chia, C., Kim, G., Shabbir, A., Willaert, W., Ong, J., Wong, J., Seo, C.J., Tan, H.L., Callebout, E., Geboes, K., Ng, M.C.H., Lum, J., Leow, W.Q., Selvarajan, S., Hoorens, A., Yong, W.P., So, J.B.Y.

Get full text

413 POSTER A phase I dose escalation study of oral SB939 when administered thrice weekly (every other day) for 3 weeks in a 4-week cycle in patients with advanced solid malignancies by Yong, W.P, Goh, B.C, Ethirajulu, K, Yeo, P, Otheris, O, Chao, S.M, Soo, R, Yeo, W.L, Seah, E, Zhu, J

Get full text

458MO Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic (met) cancers (Ca) (MEDIPAC) by Lim, J., Raghav, S., Wong, A., Yong, W.P., Soo, R.A., Chee, C.E., Lee, S.C., Goh, B-C., Dent, R.A., Chan, J.J., Wong, K.Y.K., d/o Nathan Jeraj, S., Kwok, L., Schiavon, G., Foxley, A., Tan, D.S.

Get full text

40P Phase I study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of selinexor in Asian patients with advanced solid tumour malignancies by Ho, J.S., Heong, V., Yong, W.P., Soo, R., Chee, C.E., Wong, A., Thian, Y.L., Sundar, R., Gopinathan, A., Lee, S.C., Goh, B.C., Xu, H., Tan, D.S.

Get full text

Water/Carbon Dioxide Phase Equilibria Using Thermodynamic Perturbation Theory by Yong, W.P., Awang, M.

Get full text

LBA7 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup by Yoshino, T., André, T., Kim, T.W., Yong, W.P., Shiu, K-K., Vittrup Jensen, B., Jensen, L.H., Punt, C.J.A., Smith, D., Garcia-Carbonero, R., Alcaide-Garcia, J., Gibbs, P., de la Fouchardiere, C., Rivera, F., Elez Fernandez, M.E., Le, D.T., Zuo, Y., Fogelman, D., Adelberg, D.E., Diaz, L.

Get full text

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group by André, T., Vernerey, D., Im, S.A., Bodoky, G., Buzzoni, R., Reingold, S., Rivera, F., McKendrick, J., Scheithauer, W., Ravit, G., Fountzilas, G., Yong, W.P., Isaacs, R., Österlund, P., Liang, J.T., Creemers, G.J., Rakez, M., Van Cutsem, E., Cunningham, D., Tabernero, J., de Gramont, A.

“…The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point of improving disease-free survival (DFS) with the addition of bevacizumab to…”
Get full text

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC) by Tai, W.M., Yong, W.P., Lim, C., Low, L.S., Tham, C.K., Koh, T.S., Ng, Q.S., Wang, W.W., Wang, L.Z., Hartano, S., Thng, C.H., Huynh, H., Lim, K.T., Toh, H.C., Goh, B.C., Choo, S.P.

“…Angiogenesis and RAS/RAF/MEK/ERK pathway have been demonstrated to be relevant in hepatocellular carcinoma (HCC). Sorafenib, an oral multikinase inhibitor with…”
Get full text

112P Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study by Yoshino, T., Kim, T.W., Yong, W.P., Shiu, K-K., Jensen, B. Vittrup, Jensen, L. Henrik, Smith, D., Garcia-Carbonero, R., Alcaide-Garcia, J., Gibbs, P., Fouchardiere, C. de la, Rivera, F., Elez, E., Bendell, J., Le, D.T., Yang, P., Farooqui, M., Marinello, P., Diaz, L.A., Andre, T.

Get full text

Bevacizumab as adjuvant treatment for colon cancer: Updated results from the AVANT phase III study by the GERCOR group by André, T., Vernerey, D., Im, S.-A., Bodoky, G.M., Buzzoni, R., Reingold, S., Rivera, F., McKendrick, J., Scheithauer, W., Geva, R., Fountzilas, G., Yong, W.P., Isaacs, R., Österlund, P., Liang, J.-T., Creemers, G.-J., Van Cutsem, E., Cunningham, D., Tabernero, J., De Gramont, A.

Get full text

559P - Bevacizumab as adjuvant treatment for colon cancer: Updated results from the AVANT phase III study by the GERCOR group by André, T., Vernerey, D., Im, S.-A., Bodoky, G.M., Buzzoni, R., Reingold, S., Rivera, F., McKendrick, J., Scheithauer, W., Geva, R., Fountzilas, G., Yong, W.P., Isaacs, R., Österlund, P., Liang, J.-T., Creemers, G.-J., Van Cutsem, E., Cunningham, D., Tabernero, J., De Gramont, A.

“…The AVANT study, with a median follow-up (FU) of 4 years, did not improve disease-free survival (DFS; the primary endpoint) with the addition of bevacizumab to…”
Get full text

463P - Evaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC) by Eu, J.Q., Yadav, K., Lim, Y.-C., Hirpara, J., Kong, L.R., Ng, Z.C., Lee, V.K., Lee, S.C., Tan, D.S., Soo, R.A., Chee, C.E., Yong, W.P., Sundar, R., Lim, J.S., Wang, L., Ohi, N., Tsunoda, T., Pervaiz, S., Goh, B.-C., Wong, A.L.

“…We reported that metabolic reprogramming towards OXPHOS-induced drug resistance in oncogene-addicted tumors. OXPHOS is an attractive drug target but clinical…”
Get full text

Evaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC) by Eu, J.Q., Yadav, K., Lim, Y.-C., Hirpara, J., Kong, L.R., Ng, Z.C., Lee, V.K., Lee, S.C., Tan, D.S., Soo, R.A., Chee, C.E., Yong, W.P., Sundar, R., Lim, J.S., Wang, L., Ohi, N., Tsunoda, T., Pervaiz, S., Goh, B.-C., Wong, A.L.

Get full text

Phase Ib study of safety and tolerability of selinexor in Asian patients with advanced solid cancers by Heong, V Y M, Goh, M L, Yong, W P, Soo, R A, Chee, C E, Raghav, S, Goh, B-C, Lee, S C, Lim, J, Wong, A, Tan, D S P

Get full text

Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions by Javle, M., Kelley, R.K., Roychowdhury, S., Weiss, K.H., Abou-Alfa, G.K., Macarulla, T., Sadeghi, S., Waldschmidt, D., Zhu, A.X., Goyal, L., Borad, M., Yong, W.P., Borbath, I., El-Khoueiry, A., Philip, P., Moran, S., Ye, Y., Ising, M., Lewis, N., Bekaii-Saab, T.

Get full text